argumentA line of reasoning from premises to a conclusion. Like a claim, it belongs to no one who makes it.constitution →

Outcome trials track LDL reduction across non-statin agents

forThis argument, if it holds, bears in favour of the claim.constitution →Non-statin LDL-lowering therapies reduce cardiovascular events proportionally to the LDL reduction achieved

The argument

Because linked claim and linked claim, two non-statin mechanisms independently deliver event reductions, and given the statin benchmark that linked claim, the magnitude of benefit in these non-statin trials tracks the achieved LDL reduction at a slope comparable to statins, supporting proportionality across therapies.

Does it work?

Does it follow?: likely if the premises holdIf the premises are true, the conclusion is much more likely, though not guaranteed.constitution →
Do the premises hold?: 3 verified

Suppose two non-statin mechanisms deliver benefits that match the statin slope per unit of LDL lowering. Proportionality then becomes much more likely for agents that lower LDL through the receptor pathway, though not for every non-statin therapy. All of the premises are currently verified: the statin benchmark, the PCSK9 outcome benefit and the ezetimibe outcome benefit. The argument's weakest step is that each agent's slope is estimated imprecisely.

Premises

VerifiedThe evidence, examined directly, establishes the claim.constitution →Adding ezetimibe to statin therapy reduces cardiovascular events
VerifiedThe evidence, examined directly, establishes the claim.constitution →PCSK9 inhibitors reduce cardiovascular events in statin-treated patients
VerifiedThe evidence, examined directly, establishes the claim.constitution →Statin randomized trials reduce major vascular events by about a fifth per 1 mmol/L reduction in LDL cholesterol

Where it is made

Passages where sources make, criticize or mention this argument. They record where it appears, not how strong it is, and none has precedence over another.

No source is recorded as making it.

Earlier ratings

Jul 19, 2026
The inference goes through for LDL-receptor-mediated agents, and its premises are now all verified: with linked claim and linked claim both established and the statin benchmark linked claim in place, the observed event reductions track achieved LDL lowering at a slope comparable to statins. The remaining caveat is one of reach rather than existence: proportionality is documented for relative benefit, while absolute benefit scales with baseline risk. So the argument supports proportionality across on-target LDL-lowering therapies rather than across every non-statin agent without qualification.
Jul 19, 2026
The inference goes through for LDL-receptor-mediated agents: with linked claim verified and the benchmark linked claim established, the observed event reductions track the achieved LDL reduction at a slope comparable to statins. The main caveat is that linked claim is not yet formally assessed here, though IMPROVE-IT supports it, and that proportionality holds for relative benefit while absolute benefit scales with baseline risk. So the argument supports proportionality across on-target therapies rather than across every non-statin agent without qualification.